Halozyme Therapeutics, Inc. Forecast, price target & analysts
Halozyme Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Halozyme Therapeutics, Inc. Classifications & Recommendation:
Halozyme Therapeutics, Inc. Price Target
| Target Price | $66.11 |
| Price | $57.70 |
| Potential |
14.58%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Halozyme Therapeutics, Inc. 2026 .
The average Halozyme Therapeutics, Inc. target price is $66.11.
This is
14.58%
register free of charge
$78.00
35.18%
register free of charge
$53.00
8.15%
register free of charge
|
|
| A rating was issued by 10 analysts: 6 Analysts recommend Halozyme Therapeutics, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Halozyme Therapeutics, Inc. stock has an average upside potential 2026 of
14.58%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.02 | 1.19 |
| 22.44% | 17.19% | |
| EBITDA Margin | 62.32% | 64.88% |
| 22.35% | 4.10% | |
| Net Margin | 41.60% | 45.58% |
| 33.40% | 9.57% |
9 Analysts have issued a sales forecast Halozyme Therapeutics, Inc. 2025 . The average Halozyme Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Halozyme Therapeutics, Inc. EBITDA forecast 2025. The average Halozyme Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Halozyme Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Halozyme Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 3.43 | 4.40 |
| 63.33% | 28.28% | |
| P/E | 13.10 | |
| EV/Sales | 6.76 |
8 Analysts have issued a Halozyme Therapeutics, Inc. forecast for earnings per share. The average Halozyme Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Halozyme Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Halozyme Therapeutics, Inc....
Current Halozyme Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Benchmark | Locked ➜ Locked | Locked | Feb 20 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 19 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 04 2025 |
| Wells Fargo | Locked ➜ Locked | Locked | Jan 13 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 10 2025 |
| Piper Sandler | Locked ➜ Locked | Locked | Jan 10 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 30 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Benchmark: Locked ➜ Locked
|
Feb 20 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 19 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 04 2025 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Jan 13 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Jan 10 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 30 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
